Fennec Pharmaceuticals Inc. (FENC)Healthcare | Biotechnology | Research Triangle Park, United States | NasdaqCM
6.79 USD
+0.49
(7.778%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 6.79 Short-term: ★★★★☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 1:43 a.m. EDT
While fundamentals remain fragile with negative cash flow and unprofitable operations, the current narrative is purely growth-oriented speculation on FENC's pipeline. Strong analyst upgrades and insider option grants signal confidence in a catalyst near the Q2 2025 earnings release. Pricing appears reasonable relative to the upside targets, but the lack of dividends and reliance on future drug data make this a high-delta momentum play, not a value investment. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.095925 |
| AutoTheta | 0.099773 |
| AutoETS | 0.099821 |
| AutoARIMA | 0.099822 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 47% |
| H-stat | 5.67 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.202 |
| Excess Kurtosis | -0.53 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 1.562 |
| Market Cap | 234,086,448 |
| Forward P/E | 7.37 |
| Beta | 0.93 |
| Profit Margins | -21.82% |
| Website | https://www.fennecpharma.com |
As of April 19, 2026, 1:43 a.m. EDT: Options flow shows a skewed bullish sentiment driven by deep Out-of-The-Money (OTM) call positioning. Call open interest is heavily concentrated strikes above current price (7.5, 10.0, 12.5, 15.0), suggesting speculative bets on a significant upside move by November. In contrast, put activity is substantially lower, with OI concentrated below the floor and minimal OTM put concentration. The low IV on far-dated calls alongside high implied volatility in specific strikes indicates premium for directional upside bets rather than hedging against downside crashes.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.30326295 |
| Address1 | 68 TW Alexander Drive |
| Address2 | PO Box 13628 |
| All Time High | 14.986 |
| All Time Low | 3.255 |
| Ask | 8.28 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 180,290 |
| Average Daily Volume3 Month | 166,570 |
| Average Volume | 166,570 |
| Average Volume10Days | 180,290 |
| Beta | 0.933 |
| Bid | 4.9 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 1.038 |
| City | Research Triangle Park |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.79 |
| Current Ratio | 6.374 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 6.92 |
| Day Low | 6.22 |
| Display Name | Fennec Pharmaceuticals |
| Earnings Call Timestamp End | 1,774,355,400 |
| Earnings Call Timestamp Start | 1,774,355,400 |
| Earnings Timestamp | 1,774,355,400 |
| Earnings Timestamp End | 1,778,589,000 |
| Earnings Timestamp Start | 1,778,589,000 |
| Ebitda | -6,179,333 |
| Ebitda Margins | -0.13842 |
| Enterprise To Ebitda | -31.929 |
| Enterprise To Revenue | 4.42 |
| Enterprise Value | 197,298,464 |
| Eps Current Year | 0.16833 |
| Eps Forward | 0.92167 |
| Eps Trailing Twelve Months | -0.34 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.426 |
| Fifty Day Average Change | -0.63600016 |
| Fifty Day Average Change Percent | -0.08564505 |
| Fifty Two Week Change Percent | 30.326294 |
| Fifty Two Week High | 9.92 |
| Fifty Two Week High Change | -3.13 |
| Fifty Two Week High Change Percent | -0.3155242 |
| Fifty Two Week Low | 5.02 |
| Fifty Two Week Low Change | 1.77 |
| Fifty Two Week Low Change Percent | 0.35258964 |
| Fifty Two Week Range | 5.02 - 9.92 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,505,482,200,000 |
| Float Shares | 18,836,893 |
| Forward Eps | 0.92167 |
| Forward P E | 7.3670616 |
| Free Cashflow | -7,332,250 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 35 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.91568 |
| Gross Profits | 40,878,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.14407 |
| Held Percent Institutions | 0.52978003 |
| Implied Shares Outstanding | 34,475,178 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina. |
| Long Name | Fennec Pharmaceuticals Inc. |
| Market | us_market |
| Market Cap | 234,086,448 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1455350 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -9,741,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 236,391,069 |
| Number Of Analyst Opinions | 6 |
| Open | 6.46 |
| Operating Cashflow | -12,473,000 |
| Operating Margins | -0.18538 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.47 |
| Phone | 919 636 4530 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 6.79 |
| Post Market Time | 1,776,456,605 |
| Previous Close | 6.3 |
| Price Eps Current Year | 40.337433 |
| Price Hint | 2 |
| Price To Book | 6.5414257 |
| Price To Sales Trailing12 Months | 5.243637 |
| Profit Margins | -0.2182 |
| Quick Ratio | 5.705 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.16667 |
| Region | US |
| Regular Market Change | 0.49 |
| Regular Market Change Percent | 7.77777 |
| Regular Market Day High | 6.92 |
| Regular Market Day Low | 6.22 |
| Regular Market Day Range | 6.22 - 6.92 |
| Regular Market Open | 6.46 |
| Regular Market Previous Close | 6.3 |
| Regular Market Price | 6.79 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 216,495 |
| Return On Assets | -0.06799 |
| Return On Equity | -0.65818 |
| Revenue Growth | 0.738 |
| Revenue Per Share | 1.562 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 34,475,178 |
| Shares Percent Shares Out | 0.026500002 |
| Shares Short | 913,271 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 824,295 |
| Short Name | Fennec Pharmaceuticals Inc. |
| Short Percent Of Float | 0.0352 |
| Short Ratio | 4.16 |
| Source Interval | 15 |
| State | NC |
| Symbol | FENC |
| Target High Price | 18.0 |
| Target Low Price | 13.0 |
| Target Mean Price | 15.16667 |
| Target Median Price | 15.5 |
| Total Cash | 36,788,000 |
| Total Cash Per Share | 1.067 |
| Total Debt | 0 |
| Total Revenue | 44,642,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.34 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.09065 |
| Two Hundred Day Average Change | -1.3006496 |
| Two Hundred Day Average Change Percent | -0.16075961 |
| Type Disp | Equity |
| Volume | 216,495 |
| Website | https://www.fennecpharma.com |
| Zip | 27,709 |